Ito M, Ikeno M, Nagata H, Yamamoto T, Hiroguchi A, Fox I J, Miyakawa S
Department of Surgery, Fujita-Health University, Toyoake, Aichi, Japan.
Transplant Proc. 2009 Jan-Feb;41(1):422-4. doi: 10.1016/j.transproceed.2008.10.023.
The shortage of organ donors has impeded the development of human hepatocyte transplantation. Immortalized hepatocytes, however, could provide an unlimited supply of transplantable cells. To determine whether immortalized hepatocytes could provide global metabolic support in end-stage liver disease, rat hepatocyte clones were developed by transduction with the gene encoding the simian virus 40 T antigen (SVLT) using the new technique of human artificial mini chromosome (HAC). Immortalized rat hepatocyte clones were developed by transduction with the gene encoding the SV40 using HAC. Many clones were obtained using this technique. From comparison of the properties of all these clones using the normal hepatocytes and reverse transcription-polymerase chain reaction (RT-PCR), the characteristics of the cell clones (at least partially characterized, and assayed for albumin, glucose-6-phosphate and dipeptidyl peptidase-4, gamma-glutamyltranspeptidase, SVLT and beta-actin expression by RT-PCR) showed no differences other than the immortalization. We compared the albumin bands of the first-day (0-day) and 30-day cells by RT-PCR, showing conditions to be stable for at least 1 month. Three experimental animal model groups were used for albumin analysis: nonalbumin rats with 2/3 hepatectomy only (R-NARs; n = 4); R-NARs with intrasplenic transplantation of 3 x 10(7) primary hepatocytes (pHTx; n = 4); and R-NARs with intrasplenic transplantation of 3 x 10(7) immortalized hepatocytes (iHTx; n = 4). All HTx groups produced albumin, but the immortalized hepatocyte group did not generate significantly elevated albumin levels compared with primary hepatocytes. The results presented herein have demonstrated an initial step toward the development of immortalized hepatocytes for transplantable cells or artificial organs using HAC technology.
器官供体的短缺阻碍了人类肝细胞移植的发展。然而,永生化肝细胞可以提供无限量的可移植细胞。为了确定永生化肝细胞是否能为终末期肝病提供全面的代谢支持,利用人类人工微型染色体(HAC)新技术,通过转导编码猿猴病毒40 T抗原(SVLT)的基因,培育出大鼠肝细胞克隆。通过使用HAC转导编码SV40的基因,培育出永生化大鼠肝细胞克隆。利用该技术获得了许多克隆。通过将所有这些克隆的特性与正常肝细胞进行比较,并采用逆转录聚合酶链反应(RT-PCR),细胞克隆的特性(至少部分特征已明确,并通过RT-PCR检测白蛋白、6-磷酸葡萄糖和二肽基肽酶-4、γ-谷氨酰转肽酶、SVLT和β-肌动蛋白的表达)除了永生化外没有差异。我们通过RT-PCR比较了第1天(0天)和第30天细胞的白蛋白条带,结果表明其状态至少在1个月内稳定。使用三个实验动物模型组进行白蛋白分析:仅行2/3肝切除术的无白蛋白大鼠(R-NARs;n = 4);行脾内移植3×10⁷原代肝细胞的R-NARs(pHTx;n = 4);以及行脾内移植3×10⁷永生化肝细胞的R-NARs(iHTx;n = 4)。所有肝细胞移植组均产生白蛋白,但与原代肝细胞相比,永生化肝细胞组并未产生显著升高的白蛋白水平。本文给出的结果表明,利用HAC技术开发用于可移植细胞或人造器官的永生化肝细胞迈出了第一步。